PDCD1 and melanoma: Nivolumab is an anti-PD-1-antibody, which is indicated in melanoma, lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, hepatocellular carcinoma, head and neck, urothelial and microsatellite instability-high colorectal carcinomas [83].